Additionally, heterozygous methylation of BRCA1 in BRCA1 methylated ovarian cancer PDX models is associated with PARP-is resistance, whereas complete BRCA1 methylation predicts clinical response to PARP-is [43]. This evidence concerns the gene BRCA1 and ovarian carcinoma.